drugset / Trial / NCT02323737
Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer
Phase 2
Completed
62 enrolled
Chinese Academy of Medical Sciences
China-Japan Friendship Hospital · collabChinese PLA General Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Patients with untreated extensive-stage small cell lung cancer(SCLC) were randomly assigned to receive either irinotecan/cisplatin (IP) or etoposide/cisplatin(EP), The association of efficacy and toxicity of IP regimen was analyzed.
Timeline
- Start
- 2010-07
- Primary completion
- 2011-06
- Completion
- 2012-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Etoposide | Small molecule | 100 mg/m2 | — |
| Comparator | Irinotecan | Small molecule | 65 mg/m2 | — |
| Comparator | Cisplatin | Other / unclassified | 75 mg/m2 | — |